Borroto DG, Tsuno LH, Mérida ÁO, Guerrero DC, Barceló AM

Idioma: Español
Referencias bibliográficas: 36
Paginas: 124-137
Archivo PDF: 146.32 Kb.

RESUMEN

Introducción: las complicaciones cardiovasculares son frecuentes y constituyen la principal causa de muerte en los pacientes con trasplantes renales, su alta incidencia está dada por múltiples factores de riesgo.
Objetivos: determinar la frecuencia de la hipertrofia del ventrículo izquierdo como marcador de daño cardiovascular, y los factores de riesgo que facilitarían su aparición.
Métodos: se hizo un estudio prospectivo, de corte transversal y de tipo casos y controles, a 70 enfermos con trasplantes renales a los cuales se les realizó un ecocardiograma convencional para determinar la presencia o no de hipertrofia del ventrículo izquierdo y se relacionó, mediante un estudio univariado y multivariado (regresión logística), con factores de riesgo cardiovascular.
Resultados: las afecciones cardiovasculares constituyeron la segunda causa de pérdida de los pacientes en este estudio (33,1 %), La hipertrofia del ventrículo izquierdo se encontró en 45 (64 %) de los enfermos pesquisados. La dislipemia, el uso de la ciclosporina A y la disfunción del injerto, fueron las complicaciones que constituyeron, tanto en el estudio univariado como multivariado (factor independiente), p < 0,05, condicionales que favorecieron la existencia de hipertrofia del ventrículo izquierdo, aseveraciones estas que constituyen las conclusiones de la investigación.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl. 3:S1.

2. Fellstrom B. Risk factors for and management of post transplantation cardiovascular disease. Bio Drugs. 2001;15:261.

3. Israni AK, Snyder JJ, Skeans MA, Peng Y Jr., Maclean ED, Weinhan DL, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010;10:338.

4. Fellstrom B, Jardine AG, Soveri. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant. 2005;5:1986.

5. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14:2358.

6. Boots JM, Christiaans MH, Van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047.

7. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079.

8. Liefeldt T, Budde K. Risk factors For cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant International. 2010;23:1191-204.

9. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant. 2004;4:1662.

10. Flechner SM, Goldfarb D, Solez K. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation. 2007;83:883.

11. Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis. 2010;55:152.

12. Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Tranplant. 2005;3:1-16:14.

13. Borroto G. Infecciones en el trasplante renal. Rev Cubana Med. 2002;41(3):76-9.

14. Schmidt A, Stefenelli T, Schuster E Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis. 2001;37:56-63.

15. Herzog CA, Asmger RW, Berger AK, Charyton DM, Diez J, Hart GH, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease improving global outcomes (KDIGO). Kidney International. 2011;80:572-86.

16. Vandenberg BF, Rossen JD, Grover-Mckay M, Shammas NW, Burns Trudy LR. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation. 1996;62:1230-5.

17. Taylor AJ, Cerqueira M, Hodgson JM. Appropriate use Criteria for Cardiac Computed Tomography: a Report of the American College of Cardiology Foundation. Circulation. 2010;122:e525-e555.

18. Hendel RC, Berman DS, Di Carli MF. Appropriate Use Criteria for Cardiac Radionuclide Imaging: a Report of the American College of Cardiology Foundation. Circulation. 2009;119:e561-e587.

19. Bangalore S, Yao SS, Chaudhry FA. Usefulness of stress echocardiography for risk stratification and prognosis of patients with left ventricular hypertrophy. Am J Cardiol. 2007;100:536-43.

20. Sharma R, Mehta RL, Brecker SJ. The diagnostic and prognostic value of tissue Doppler imaging during dobutamine stress echocardiography in end-stage renal disease. Coron Artery Dis. 2009;20:230-7.

21. Arnol M, Knap B, Oblak M, Buturoviæ-Ponikvar J, Bren AF, Kandus A. Subclinical left ventricular echocardiographic abnormalities 1 year after kidney transplantation are associated with graft function and future cardiovascular events. Tranplantation Proc. 2010;42:4064-8.

22. Dzemidziæ J, Rasiæ S, Saraceviæ A. The influence of renal alograft function on cardiovscular status and left ventricular remodelling. Bos J Basic Med Sci. 2009;9:102-6.

23. Patel RK, Jardine AG, Mark PB, Cunningham AF, Steedman T, Powell JR, et al. Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis. 2010;55:1088-96.

24. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745.

25. Henry RM, Kostense PJ, Bos G. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002;62:1402.

26. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291.

27. Fellstrom B, Jardine AG, Soveri I. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant. 2005;5:1986.

28. Curtis J. Corticosteroids and kidney transplantation. Clin J Am Soc Nephrol. 2006;1:907-8.

29. Kirkpontour A, Yilmaz R. Utility of C2 monitoring in prediction of diastolic dysfunction in renal transplant recipients. Tranplantation Proc. 2008;40:171-3.

30. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 2002;62:2257.

31. Arjang D, Pitrangeli C, Gordon RD, Legendre C. Potential strategies to improve the postransplant cardiovascular risk profile. Kidney Int. 2010;78(S-118):S15-S21.

32. Schena FP, Pascoe MD. Conversion from calcineurins inhibitors to sirolimus maintenance theraphy in renal allograft recipients.: 24 month efficacy and safety results from the COVERT trial. Transplantation. 2009;87:233-42.

33. Ekbert H, Tedesco-Silva H. Reduce exposure to calcineurin inhibitors in renal transplantation. N Eng J Med. 2007;357:2562-75.

34. Gallagher M, Jardine M, Perkovic V, Cass A, McDonald S, Petrie J, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation. 2009;87:1877.

35. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis. 2008;52:324.

36. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008;3 Suppl. 2:S101.